Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine

摘要: In previous trials, bevacizumab failed to prolong the overall survival time in newly diagnosed glioblastoma and at first recurrence. Randomized clinical trials second or further recurrence following failure of radiotherapy, temozolomide lomustine, retrospective analyses focusing on this specific cohort, are not yet available. A total 62 patients with who received after standard care, including were retrospectively identified. Patient characteristics, treatment details, concomitant therapy, response based Response Assessment Neuro-Oncology criteria, progression-free (PFS) (OS) times rates evaluated. Furthermore, PFS OS analyzed for responders non-responders. Of patients, 54.8% (n=34) responded [complete (CR) 3.2%, n=2; partial (PR) 51.6%, n=32]. The median was 3.5 months 7.5 months. rate 6 21.5% 12 11.5%. Responders (CR PR) experienced a superior compared non-responders (i.e. stable progressive disease; 5.4 vs. 1.9 months; P<0.0001) (34.9 7.1%; P<0.0001). (8.6 6.4 (21.3 0%; also exhibited treatment. conclusion, objective indicate that has activity temozolomide, lomustine. randomized trial comparing best supportive care these is advised.